Literature DB >> 14500030

Downregulation of PPARgamma expression in peripheral blood monocytes correlated with adhesion molecules in acute coronary syndrome.

Shui Ping Zhao1, Yi Fu Li.   

Abstract

BACKGROUND: Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a nuclear hormone receptor and may regulate the metabolism of lipids, inhibit monocytes/macrophages function and reduce the production of cell adhesion molecules and some inflammatory factors. Thus, it may affect the occurrence and progression of atherosclerosis.
METHODS: Forty-three patients with acute coronary syndrome and 34 control subjects were studied for PPARgamma expression in peripheral blood monocytes by reverse transcription-polymerase chain reaction (RT-PCR), and adhesion molecules were measured by enzyme-linked immunosorbent assay (ELISA).
RESULTS: Expression of PPARgamma in peripheral blood monocytes was significantly reduced in acute coronary syndrome, which was inversely associated with intercellular adhesion molecule 1 (r=-0.339, P<0.05), vascular cell adhesion molecule 1 (r=-0.331, P<0.05) and body mass index (r=-0.334, P<0.05), respectively, and positively correlated with apoA1 (r=0.289, P<0.05).
CONCLUSIONS: The reduced expression of PPARgamma in peripheral blood monocytes of patients with acute coronary syndrome is inversely associated with plasma soluble adhesion molecules, suggesting that PPARgamma may be involved in acute coronary syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500030     DOI: 10.1016/s0009-8981(03)00290-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

1.  Arisaema heterophyllum Blume Monomer Stigmasterol Targets PPARγ and Inhibits the Viability and Tumorigenicity of Lung Adenocarcinoma Cells NCI-H1975.

Authors:  Na Song; Jing Wang; Zonglang Lai; Shuting Liang; Wenjuan Zou; Juan Wang; Dandan Zheng; Ying Li; Yuxi He; Jun Cheng; Yue Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-20       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.